Document Detail


Review of Chinese clinical trials on CIK cell treatment for malignancies.
MedLine Citation:
PMID:  22301398     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
China is the country where the most clinical trials on CIK cells have been performed. We aimed to provide definite evidence for using CIK cell treatment and extrapolate a common applicative standard for malignancies. We chose the VIP database of Chinese scientific and technological journals to search the literature. We entered the keywords "CIK" or "xi bao yin zi you dao de sha shang xi bao" (the equivalent Chinese phrase for CIK cells, by Chinese characters) and searched for in vivo human trials. In 24 collected trials, 936 patients were treated with CIK cells, 525 men and 246 women. The cultivation time of CIK cells ranged from 7 to 28 days. In five studies, CIK cells were co-cultured with dendritic cells. The total number of CIK cells used ranged from 6×10(6) to 1.5×10(10). The total number of DC-CIK cells used ranged from 1×10(9) to 1.3×10(10). In all studies, those immune parameters and tumour markers examined increased, but not all increased significantly. Of the reported 563 patients, 40 had a complete response, 126 had a partial response, 125 had a minimal response, 135 had stable disease and 58 had progressive disease. The remaining 76 patients did not reach an objective response. The total response rate was 51.7% (291/563). The toxicities were slight. CIK cell treatment is a promising and safe modality for treating malignancies. We proposed a standard for cultivating CIK cells.
Authors:
X D Li; B Xu; J Wu; M Ji; B H Xu; J T Jiang; C P Wu
Related Documents :
21217828 - No relationship between embryo morphology and successful derivation of human embryonic ...
11407148 - A comparative study on oncostatin m secretion by transplantable melanoma cells with reg...
15165318 - Hyalinizing clear cell carcinoma of the hard palate.
19649148 - Current concepts of metastasis in melanoma.
1333358 - Abnormal chloride conductance in multidrug resistant hl60/ar cells.
23303808 - Pathogenic brucellae replicate in human trophoblasts.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico     Volume:  14     ISSN:  1699-3055     ISO Abbreviation:  Clin Transl Oncol     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101247119     Medline TA:  Clin Transl Oncol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  102-8     Citation Subset:  IM    
Affiliation:
Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou 213003, People's Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.
Next Document:  Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-bo...